Jubilant Pharmova eyes $150 mn via rupee debt sale

What happened: Jubilant Pharmova plans to raise around 14 billion rupees through the sale of three-year bonds with bullet maturity, according to bankers. The company did not reply to a Reuters request for comment. Key numbers: About 14 billion rupees (around $150 million); three-year bonds with bullet maturity; AA+ rating from India Ratings; the company could tap the debt market before the end of next month. Why it matters: India Ratings expects the company's business profile to strengthen over the medium term, supported by increasing contribution from recently commissioned capacities.

Jubilant Pharmova plans to raise around 14 billion rupees through the sale of three-year bonds with bullet maturity, according to bankers. The company did not reply to a Reuters request for comment.

India Ratings expects the company's business profile to strengthen over the medium term, supported by increasing contribution from recently commissioned capacities.